Aguilar-Rabiela Arturo E, Homaeigohar Shahin, González-Castillo Eduin I, Sánchez Mirna L, Boccaccini Aldo R
Institute of Biomaterials, Department of Materials Science and Engineering, University of Erlangen-Nuremberg, Cauerstrasse 6, 91058 Erlangen, Germany.
Tissue Engineering Research Group, Department of Anatomy & Regenerative Medicine, Royal College of Surgeons in Ireland (RCSI), D02 YN77 Dublin, Ireland.
Polymers (Basel). 2023 May 24;15(11):2432. doi: 10.3390/polym15112432.
In recent years, composite biomaterials have attracted attention for drug delivery applications due to the possibility of combining desired properties of their components. However, some functional characteristics, such as their drug release efficiency and likely side effects, are still unexplored. In this regard, controlled tuning of the drug release kinetic via the precise design of a composite particle system is still of high importance for many biomedical applications. This objective can be properly fulfilled through the combination of different biomaterials with unequal release rates, such as mesoporous bioactive glass nanoparticles (MBGN) and poly(3-hydroxybutyrate--3-hydroxyvalerate) (PHBV) microspheres. In this work, MBGNs and PHBV-MBGN microspheres, both loaded with Astaxanthin (ASX), were synthesised and compared in terms of ASX release kinetic, ASX entrapment efficiency, and cell viability. Moreover, the correlation of the release kinetic to phytotherapeutic efficiency and side effects was established. Interestingly, there were significant differences between the ASX release kinetic of the developed systems, and cell viability differed accordingly after 72 h. Both particle carriers effectively delivered ASX, though the composite microspheres exhibited a more prolonged release profile with sustained cytocompatibility. The release behaviour could be fine-tuned by adjusting the MBGN content in the composite particles. Comparatively, the composite particles induced a different release effect, implying their potential for sustained drug delivery applications.
近年来，复合生物材料因其各组分所需特性的可组合性而在药物递送应用中受到关注。然而，一些功能特性，如药物释放效率和可能的副作用，仍未得到探索。在这方面，通过精确设计复合粒子系统来控制药物释放动力学对于许多生物医学应用仍然至关重要。通过将具有不同释放速率的不同生物材料，如介孔生物活性玻璃纳米颗粒（MBGN）和聚（3-羟基丁酸酯-3-羟基戊酸酯）（PHBV）微球相结合，可以恰当地实现这一目标。在这项工作中，合成了均负载虾青素（ASX）的MBGNs和PHBV-MBGN微球，并在ASX释放动力学、ASX包封效率和细胞活力方面进行了比较。此外，还建立了释放动力学与植物治疗效率和副作用之间的相关性。有趣的是，所开发系统的ASX释放动力学之间存在显著差异，72小时后细胞活力也相应不同。两种颗粒载体都能有效递送ASX，尽管复合微球表现出更长的释放曲线和持续的细胞相容性。通过调整复合颗粒中MBGN的含量，可以对释放行为进行微调。相比之下，复合颗粒诱导了不同的释放效果，这意味着它们在持续药物递送应用中的潜力。
